Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s

[Farooqji]

Primary analyses from this phase 3 clinical trial of the investigational, subcutaneous infusion of levodopa/carbidopa (LD/CD) (ND0612) showed that treatment in doses of up to 720 mg/90 mg per day, supplemented with oral levodopa provided almost 2 additional hours per day of “Good On” time without troublesome dyskinesia compared with immediate-release levodopa/carbidopa (IR-LD/CD) at week 12.

healio.com/news/neurology/2...